A clinical trial has been launched in Argentina to see if a shorter regimen of the drug benznidazole has the potential to become a new standard treatment for Chagas disease to treat adult patients in the...
Chagas disease is a potentially life-threatening parasitic disease that affects up to 300,000 people in the United States and millions in South America.
The current treatment regimen is–oral benznidazole...
By NewsDesk @bactiman63
Researchers in the University of Georgia’s Center for Tropical and Emerging Global Diseases have found that a more intensive, less frequent drug regimen with currently...
The World Health Organization (WHO) and the Mundo Sano Foundation are working to make an essential antiparasitic medicine for treatment of Chagas disease widely accessible to children. Treatment with benznidazole...
The U.S. Food and Drug Administration today granted accelerated approval to benznidazole for use in children ages 2 to 12 years old with Chagas disease. It is the first treatment approved in the United...
California based biopharmaceutical company, KaloBios Pharmaceuticals, Inc. yesterday announced positive guidance in the minutes from a recent meeting with the U.S. Food and Drug Administration (FDA) to...
Privacy Overview
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
